Insilico joins industry collaboration on microbial genome research

30 December 2008

(Stuttgart, Düsseldorf) – Insilico Biotechnology AG enters a consortium of leading companies in the chemicals, pharmaceuticals and nutrition industries pooling forces on microbial genome research. Industry and BMBF will provide around 600 million Euros for white biotechnology over the next decade.

In 2006, prominent companies in the chemicals, pharmaceuticals and nutrition industries have come together for the first time under the umbrella of the »Industrieverbund Mikrobielle Genomforschung« (industry association to promote microbial genome research IMG), Düsseldorf, with the aim of advancing microbial genome research as a technology with broad industrial application. Over the next years, the industry collaboration will seek to improve the efficiency of micro-organisms that are used in technical processes and to develop new products from micro- organisms with novel properties. This work will substantially promote development of sustainable chemicals and white biotechnology in Germany, further strengthening its pioneering role in this technology in both academic research and industrial application. Industry and the Federal Ministry for Education and Research (BMBF) will provide around 600 million Euros for white biotechnology projects over the next ten years.

Dr. Karl-Heinz Maurer, Chairman of the Industrieverbund Mikrobielle Genomforschung, comments: »The collaboration initiative IMG is particularly proud of its portfolio of small, medium and large companies spanning a broad range of young, technology-driven biotech companies like, for example, Insilico Biotechnology to companies serving various markets for several years. The initiative is gaining further momentum and we are currently talking to yet other highly interested companies.«

Klaus Mauch, CEO of Insilico Biotechnology, adds »Providing new solutions in the post-genomic era requires a work-sharing approach, pooling specialised partners ranging from fast sequencing and computational target identification on high-performance clusters to implementing novel and improved processes in vivo. The industry association forms an excellent platform for building alliances covering the complete value chain in modern biotechnological research and development. First results are already on track.«

Insilico Biotechnology designs and optimises biotechnological processes for the chemical, food, agro, and healthcare industries. Successful in business since 2001, Insilico provides internationally renowned expertise and a unique technology platform. Insilico’s competitive advantage is its proven track record of producing innovative solutions and IP for customers using in silico cells and computing facilities. By building better and highly integrated models of complex cellular processes, Insilico sets new standards as a leading provider to the Life Sciences industries. Insilico is a privately-owned company, located in Stuttgart, Germany.

Industrieverbund Mikrobielle Genomforschung e.V. (Düsseldorf): An association to promote science, research and pharma industry, in particular functional genome research into micro-organisms. The association brings together the experience gained by science and business, supports research in the area of genome research and supports the exchange of expertise and cooperation between business and science. Members of the Industrieverbund come from companies in the biotechnology, chemicals, consumer goods, foodstuffs and pharmaceuticals industries. Current members are Agowa, Bayer CropScience, Biopract, BRAIN, Ciba Specialty Chemicals, EUROFINS MWG, Evonik Industries, EVOcatal, febit biotech, GATC Biotech, Genedata, Henkel, Insilico Biotechnology, Milupa, Sandoz Industrial Products, Silantes, Südzucker, Symrise and Wacker Chemie.


Insilico Biotechnology AG
Klaus Mauch | CEO
T +49 711 674 2164
F +49 711 674 2166
klaus.mauch [at]

Industrieverbund Mikrobielle Genomforschung e.V. (IMG)
c/o Dr. K.-H. Maurer
T +49 211 797 3039
F +49 211 798 8958
karl-heinz.maurer [at]